Analyst: Buy This Penny Stock Before Earnings

Roth Capital's new SRTS price target is lofty

Aug 1, 2018 at 12:03 PM
facebook twitter linkedin

The shares of medical technology concern Sensus Healthcare Inc (NASDAQ:SRTS) are higher today, with help from some bullish analyst attention. Specifically, ahead of the company's turn in the earnings spotlight tomorrow, Aug. 2, Roth Capital launched coverage of SRTS stock with a "buy" rating and $12.50 price target -- a premium of 83% to yesterday's close. At last check, Sensus shares were up 2.4% at $6.97.

SRTS shares have pulled back some since touching a record high of $7.71 in mid-June. However, the stock seems to have found support in the $6.60 area, which acted as a ceiling shortly after Sensus Healthcare's initial public offering (IPO) in mid-2016. Further, this area is roughly double the security's all-time low of $3.38, touched last July.

SRTS stock chart aug 1

SRTS is no stranger to upbeat analyst attention, however, especially considering the shares have added more than 76% in the past year. Currently, all three analysts following the equity deem it worthy of a "buy" rating. Plus, the consensus 12-month price target of $9.75 represents a premium of nearly 40% to the stock's current perch.


If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!



Special Offers from Schaeffer's Trading Partners